What's Happening?
Schrödinger, Inc. has announced a collaboration with Eli Lilly and Company to integrate Lilly's TuneLab platform into Schrödinger's LiveDesign enterprise informatics platform. TuneLab, designed to accelerate
drug discovery and development, will be accessible to participating biotech companies through LiveDesign, providing advanced AI capabilities. This partnership aims to democratize access to AI models, physics-based calculations, and experimental data across discovery teams, enhancing collaborative decision-making in drug discovery.
Why It's Important?
The collaboration between Schrödinger and Lilly represents a significant advancement in the field of computational drug discovery. By integrating TuneLab into LiveDesign, the partnership aims to streamline workflows and improve the efficiency of drug development processes. This integration could lead to faster and more cost-effective discovery of novel therapeutics, benefiting patients and the pharmaceutical industry. The use of AI and machine learning in drug discovery is becoming increasingly important, and this collaboration highlights the potential for technology to transform the way new drugs are developed.
What's Next?
As Schrödinger and Lilly move forward with this collaboration, they will focus on expanding the use of digital drug design methods and driving greater impact for patients. The integration of TuneLab into LiveDesign is expected to enhance the capabilities of both platforms, providing a unified solution for drug discovery teams. The partnership may also lead to further collaborations with other biotech companies, leveraging the strengths of both Schrödinger and Lilly to advance the field of computational drug discovery. The success of this collaboration could pave the way for future innovations in the pharmaceutical industry.
